BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25381384)

  • 1. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
    Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
    Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
    Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK; Messina J; Xie F; Peppin J
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.
    Mercadante S; Porzio G; Aielli F; Averna L; Ficorella C; Casuccio A
    Support Care Cancer; 2013 Aug; 21(8):2335-9. PubMed ID: 23564072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
    Mercadante S
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain.
    Kleeberg UR; Davies A; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
    Eur J Pain; 2015 Apr; 19(4):528-37. PubMed ID: 25181451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
    Masel EK; Landthaler R; Gneist M; Watzke HH
    Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
    Shimoyama N; Gomyo I; Katakami N; Okada M; Yukitoshi N; Ohta E; Shimoyama M
    Int J Clin Oncol; 2015 Feb; 20(1):198-206. PubMed ID: 24839047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control.
    Chiang YH; Lien CT; Su WH; Yen TY; Chen YJ; Lai YL; Lim KH; Dai KY; Chung HP; Hung CY; Leu YS
    BMC Palliat Care; 2024 Jun; 23(1):150. PubMed ID: 38877477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
    De Franceschi L; Mura P; Schweiger V; Vencato E; Quaglia FM; Delmonte L; Evangelista M; Polati E; Olivieri O; Finco G
    Pain Pract; 2016 Jul; 16(6):680-7. PubMed ID: 26009799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain.
    Davies A; Kleeberg UR; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
    Support Care Cancer; 2015 Jul; 23(7):2135-43. PubMed ID: 25556611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study.
    Mercadante S; Adile C; Cuomo A; Aielli F; Cortegiani A; Casuccio A; Porzio G
    J Pain Symptom Manage; 2015 Nov; 50(5):579-86. PubMed ID: 26303188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.
    Passik SD; Narayana A; Yang R
    Pain Med; 2014 Aug; 15(8):1365-72. PubMed ID: 24666664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer.
    Blick SK; Wagstaff AJ
    Drugs; 2006; 66(18):2387-93; discussion 2394-5. PubMed ID: 17181383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
    Portenoy RK; Taylor D; Messina J; Tremmel L
    Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.